Press Releases

• • All Categories
  • C. difficile
  • Chikungunya
  • COVID-19
  • DUKORAL®
  • IXIARO®
  • Lyme Disease
  • Uncategorized

Filter By Year 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007

April 30, 2008

VIVALIS ANNOUNCES THE FILING OF ITS FIRST ANNUAL REGISTRATION DOCUMENT

April 16, 2008

Quarterly report: 1st Quarter 2008 Cash position of € 22, 8 million Objectives for 2008: Signing of 7 to 9 new EBx® licenses, including 2 commercial licenses

April 14, 2008

VIVALIS WILL PARTICIPATE IN THE SMALL CAP EVENT IN PARIS ON APRIL 21 AND 22, 2008

April 1, 2008

VIRBAC EXERCISES ITS OPTION FOR A COMMERCIAL LICENCE AGREEMENT TO USE VIVALIS’ EBx® PLATFORM FOR THE PRODUCTION OF SEVERAL VACCINES.

March 31, 2008

2007: a major stage in the development of VIVALIS: 4 years of financial visibility and acceleration of R&D programmes 26 partnerships with 22 of the largest operators in the pharmaceutical industry

February 14, 2008

Quarterly report: 4th quarter 2007 High visibility on the activity: cash position of M€ 24.9 covering 4 years of operations.

February 5, 2008

VIVALIS STRENGTHENS ITS HUMAN AND TECHNICAL RESSOURCES IN THE FIELD OF THERAPEUTIC PROTEINS

January 29, 2008

VIVALIS AND KAKETSUKEN EXTEND THEIR COLLABORATION IN THE TESTING OF VIVALIS EBx® CELLS FOR THE PRODUCTION OF HUMAN AND VETERINARY VIRAL VACCINES

January 21, 2008

VIVALIS AND INNATE PHARMA SIGN A COLLABORATION AND COMMERCIAL LICENSE AGREEMENT TO DEVELOP INNATE’S NOVEL MONOCLONAL ANTIBODY, TO BE MANUFACTURED WITH VIVALIS’ EB66® PLATFORM, FOR RARE CUTANEOUS CANCERS

January 8, 2008

VIVALIS ISSUES ITS FINANCIAL CALENDAR 2008